ERS Genomics Limited (ERS), a biotechnology company, announced a new license agreement with Lepton Pharmaceuticals LTD (Lepton). This is a non-exclusive licensing agreement granting Lepton access to the ERS CRISPR/Cas9 patent portfolio for certain applications.
ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 90 patents are held in over eighty countries.
Lepton Pharmaceutical LTD is a biotechnology company developing a proprietary, breakthrough technology (Castling Technology) to substantially improve adaptive cell-mediated immune response (T-cells, CAR-T-cells, NK-cells.)
Dr. Daniel Zurr, CEO of Lepton said:
